Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
MWN-AI** Summary
Bausch + Lomb, a prominent global eye health company, is taking proactive steps to combat the rising concern of glaucoma, a leading cause of irreversible blindness affecting approximately four million people in the U.S. To promote awareness and funding for this critical issue, the company is collaborating with the Glaucoma Research Foundation (GRF) and The Glaucoma Foundation (TGF) during Glaucoma Awareness Month in January.
This partnership will feature the fifth annual fundraising challenge, where Bausch + Lomb will match every dollar raised, up to $20,000, specifically for glaucoma research initiatives. Additionally, as part of a month-long awareness campaign, Bausch + Lomb will sponsor TGF’s efforts to share stories from glaucoma patients and advocates daily throughout January. This initiative aims to highlight the experiences of those living with glaucoma and emphasize the importance of early detection and intervention to mitigate the disease's effects.
Andrew Stewart, president of Global Pharmaceuticals and International Consumer at Bausch + Lomb, indicated that the aging population is likely to increase glaucoma cases and stressed the significance of education and research in improving patient outcomes. Similarly, leaders from GRF and TGF reinforce the necessity of public awareness and research funding, affirming that this condition often progresses without noticeable symptoms, making timely diagnosis critical.
Together, these organizations aim to foster greater understanding of glaucoma, motivate proactive eye health measures, and ultimately work towards better treatments and potential solutions for this debilitating disease. Through their collaborative efforts, they hope to not only support individuals affected by glaucoma but also drive innovation in eye health research, ultimately fostering a future where sight can be preserved for all.
MWN-AI** Analysis
Bausch + Lomb’s recent partnership with the Glaucoma Research Foundation (GRF) and The Glaucoma Foundation (TGF) to address glaucoma is a strategic move that reflects the company’s commitment to both corporate social responsibility and innovation in eye health. As a leading cause of irreversible blindness impacting approximately four million people in the U.S., glaucoma presents substantial market opportunities for companies actively involved in research and advocacy.
This initiative coinciding with Glaucoma Awareness Month positions Bausch + Lomb as a leader in the sector, enhancing its brand equity and public image. By matching donations up to $20,000, the company is not only fostering goodwill but also driving funds towards critical research that can lead to breakthrough treatments. The collaborative effort to raise awareness through TGF’s social media campaign adds human interest, showcasing real patient stories and emphasizing the importance of early detection.
Investors should note that initiatives like these can significantly boost Bausch + Lomb’s visibility and stakeholder engagement, translating into long-term financial performance. The company's involvement in educational efforts enhances customer loyalty, potentially increasing sales in its eye health products. Furthermore, as the prevalence of glaucoma is expected to rise with an aging population, Bausch + Lomb is well-positioned to capture a larger market share by offering innovative, responsive solutions.
Looking ahead, stakeholders may wish to monitor the outcomes of this partnership closely. Success in advancing glaucoma research could result in new product lines or treatments, providing Bausch + Lomb with a competitive edge. In an evolving market, strategic investments in health education and research partnerships can yield substantial returns, making Bausch + Lomb an attractive option for investors focused on socially responsible companies with strong growth potential in the healthcare sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research
- Bausch + Lomb will also sponsor The Glaucoma Foundation’s annual month-long educational social media campaign, which spotlights stories from glaucoma patients and advocates
- Glaucoma affects about four million people in the United States 1
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in January. Bausch + Lomb will also sponsor The Glaucoma Foundation’s (TGF) social media campaign to raise awareness of the disease and its impact by highlighting a glaucoma patient or advocate every day in January.
“Currently, about four million people in the United States are affected by glaucoma, and this number is only expected to grow as the population ages,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. “Our collaborations with GRF and TGF will advance education and research efforts designed to improve the lives of those affected by glaucoma and encourage everyone to be proactive when it comes to eye health.”
As part of the fundraising challenge with GRF, Bausch + Lomb will match every dollar raised during January, up to $20,000. All proceeds will support critical research for glaucoma, a leading cause of irreversible blindness in the U.S. 1
“Glaucoma often progresses without noticeable symptoms, making research and improved education vital to saving sight,” said Thomas M. Brunner, president and CEO, Glaucoma Research Foundation. “Our continued partnership with Bausch + Lomb supports our efforts to accelerate the discoveries that can make a real difference for people living with this disease.”
Learn more about GRF or make a donation at www.glaucoma.org .
TGF’s social media campaign aims to put a human face to the disease, raise awareness and stress the importance of early detection by sharing personal stories from a patient or advocate each day during the month of January.
“Due to the chronic, progressive nature of glaucoma, early intervention can mean the difference between saving and losing sight,” said Elena Sturman, president and CEO, The Glaucoma Foundation. “In partnership with Bausch + Lomb, our campaign will showcase real-world experiences with glaucoma, create greater awareness and bring hope to those affected by this disease.”
Learn more about The Glaucoma Foundation at www.glaucomafoundation.org and follow the organization on Facebook , Instagram , LinkedIn and X to experience the social media campaign throughout Glaucoma Awareness Month.
About Glaucoma
Glaucoma is a chronic, progressive disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. The optic nerve is responsible for the communication of information between the eye and brain. Damage to the optic nerve can lead to severe vision loss, and in the worst case, blindness. As the leading cause of irreversible blindness, glaucoma affects about four million people in the United States, but if caught early, it is possible to help slow and potentially prevent vision loss. 1-3
About Bausch + Lomb
Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we’ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we’re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook , Instagram , LinkedIn , X and YouTube .
About Glaucoma Research Foundation
Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. GRF funds glaucoma research worldwide and serves as the leading information source for patients and their families. Founded in 1978 in San Francisco, GRF was created to encourage innovative research to find better ways to care for people with glaucoma — the leading cause of preventable blindness. Since its inception, GRF has invested more than $90 million to fund breakthrough research to better understand, detect, and treat glaucoma.
About The Glaucoma Foundation
Since 1984, The Glaucoma Foundation has worked to identify, encourage, and fund scientific research into the potentially blinding disease of glaucoma, with the goal of eradicating vision loss and blindness from glaucoma. Through education and outreach, we strive to be a valuable resource to improve the lives of those affected by the disease.
References
- Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol . 2024;142(11):1046–1053. doi:10.1001/jamaophthalmol.2024.3884
- John Hopkins. Glaucoma. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma . Reviewed on Nov. 7, 2025.
- National Eye Institute. Glaucoma and Eye Pressure. Retrieved from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure . Reviewed on Nov. 7, 2025.
© 2025 Bausch + Lomb.
BLNP.0137.USA.25
View source version on businesswire.com: https://www.businesswire.com/news/home/20260105643250/en/
Bausch + Lomb Media Contact
Caryn Marshall
caryn.marshall@bausch.com
(908) 493-1381
Glaucoma Research Foundation Media Contact:
Andrew J. Jackson
ajackson@glaucoma.org
(415) 986-3162
The Glaucoma Foundation Media Contact:
Gabrielle Bamberger
gbprbiz@verizon.net
917-273-7382
FAQ**
How does Bausch + Lomb Corporation (BLCO) plan to leverage its partnerships with the Glaucoma Research Foundation and The Glaucoma Foundation to enhance glaucoma awareness and research funding during Glaucoma Awareness Month?
2. What impact does Bausch + Lomb Corporation (BLCO) anticipate from matching donations during its fifth annual fundraising challenge for glaucoma research, particularly in addressing the rising number of affected individuals in the U.S.?
3. Can Bausch + Lomb Corporation (BLCO) provide specific examples of how funds raised during the fundraising challenge will be allocated to improve education and research efforts related to glaucoma?
4. How does Bausch + Lomb Corporation (BLCO) evaluate the success of its initiatives for glaucoma awareness, such as the social media campaign in partnership with The Glaucoma Foundation and the fundraising challenge with the Glaucoma Research Foundation?
**MWN-AI FAQ is based on asking OpenAI questions about Bausch + Lomb Corporation (NYSE: BLCO).
NASDAQ: BLCO
BLCO Trading
-3.76% G/L:
$16.25 Last:
157,922 Volume:
$16.57 Open:
